Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdansk – page 59

865 clinical trials in Gdansk, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdansk at a glance
865
clinical trials
  • Research sites11
Type of trial
Recruitment status
Quick filters

865 trials in Gdansk

Open in trial search

Non-small cell lung cancer+2

Not recruiting

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer+1

Not recruiting

Study of Alectinib and Platinum-Based Chemotherapy for Patients with Resected Stage Ib to IIIa ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Squamous cell carcinoma of skin

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mrna-4157
  • Sponsor:Merck Sharp & Dohme LLC

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
  • Sponsor:Recognify Life Sciences Inc.

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Children with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Type 2 diabetes mellitus

Not recruiting

Study on the Effectiveness and Safety of Adding Pioglitazone to Metformin and Empagliflozin for Patients with Type 2 Diabetes with Poor Blood Sugar Control

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Celltrion Inc.

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Asthma

Not recruiting

Study on the Effects of Povorcitinib for Adults with Moderate to Severe Asthma Not Well Controlled

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Fatty acid oxidation disorder

Not recruiting

Study on the Effects of Triheptanoin and Medium-chain Triglycerides in Children with Long-chain Fatty Acid Oxidation Disorders

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Doconexent
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdansk

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on bladder cancer, lymphoma, and various advanced solid tumors. Studies are evaluating novel combination therapies and investigating treatments for non-small cell lung cancer.

  • Bladder Cancer Immunotherapy
  • B-Cell Lymphoma Treatment
  • Gastric Cancer Therapeutics

Research includes promising approaches combining established treatments with new immunotherapy agents.

02 Dermatology Studies

Clinical investigations targeting plaque psoriasis, genital psoriasis, and atopic dermatitis. Studies are examining oral and subcutaneous treatments for moderate to severe skin conditions.

  • Psoriasis Management
  • Hidradenitis Suppurativa
  • Novel Dermatological Therapies

Focus on developing targeted treatments for chronic skin conditions affecting quality of life.

03 Metabolic Disorders

Comprehensive research into obesity and weight management, including studies for patients with and without type 2 diabetes. Trials are evaluating new therapeutic approaches for weight reduction.

  • Weight Management Solutions
  • Diabetes Treatment
  • Cardiovascular Risk Management

Investigation of innovative treatments combining lifestyle modifications with pharmaceutical interventions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.